Bluebird bio Inc BLUE
Dividend Summary
There have not been any declared dividends recently.
Summary | Previous dividend | Next dividend |
---|---|---|
Status | – | – |
Type | – | – |
Per share | – | – |
Declaration date | – | – |
Ex-div date | – | – |
Pay date | – | – |
Enter the number of Bluebird bio Inc shares you hold and we'll calculate your dividend payments:
Sign up for Bluebird bio Inc and we'll email you the dividend information when they declare.
Add Bluebird bio Inc to receive free notifications when they declare their dividends.
Your account is set up to receive Bluebird bio Inc notifications.
Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
---|---|---|---|---|---|---|---|---|
There are no Bluebird bio Inc dividends. |
Year | Amount | Change |
---|---|---|
2006 | 0.0c | — |
2007 | 0.0c | 0% |
2008 | 0.0c | 0% |
2009 | 0.0c | 0% |
2010 | 0.0c | 0% |
2011 | 0.0c | 0% |
2012 | 0.0c | 0% |
2013 | 0.0c | 0% |
2014 | 0.0c | 0% |
2015 | 0.0c | 0% |
2016 | 0.0c | 0% |
2017 | 0.0c | 0% |
2018 | 0.0c | 0% |
2019 | 0.0c | 0% |
2020 | 0.0c | 0% |
2021 | 0.0c | 0% |
2022 | 0.0c | 0% |
2023 | 0.0c | 0% |
2024 | Sign Up Required |
Bluebird bio Inc Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 17 October 2023
- 52 Week Low
- 0.0% on 17 October 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Bluebird bio Inc
Bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United States
- Share Price
- $0.48 (yesterday's closing price)
- Shares in Issue
- 194 million
- Market Cap
- $93mn
- 0
- Market Indices
- none